Objective:

To discuss the urgent reimbursement challenges faced by ASCs and eye banks regarding corneal tissue procedures and their significant impact on patient care.

Key Findings:

• Corneal tissue procedures are essential for patient outcomes but are low in volume compared to cataract surgeries.
• Under-reimbursement from Medicare Advantage and private insurers can delay patient care and strain financial resources of ASCs and eye banks, potentially leading to fewer procedures being performed.
• Eye banks cannot mark up corneal tissue costs, leading to potential losses if discounts are provided, which may ultimately affect patient access to transplants.

Interpretation:

The reimbursement landscape for corneal tissue is complex and often unfavorable, significantly impacting the availability of sight-saving procedures for patients and potentially leading to worse health outcomes.

Limitations:

• The article does not provide specific data on the financial impact of under-reimbursement on ASCs and eye banks.
• Limited discussion on potential policy changes or broader systemic solutions to address reimbursement issues, and lacks patient perspectives or qualitative data.

Conclusion:

ASCs should seek expert guidance when negotiating contracts with insurers and consider specific strategies to advocate for better reimbursement terms to ensure that corneal transplant procedures remain accessible to patients.